Evidence map›Paper›PMID 32514680›Full record

ArticleClinical rheumatology2021

Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study.

Xinyi Li, Xiaoli Deng, Hongji Duan, Lin Zeng, Jiansuo Zhou, Chang Liu, Xiaoyue Guo, Xiangyuan Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Article
  9. The pathogenesis of obstetric APS: a 2023 update.Clinical immunology (Orlando, Fla.) · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xinyi LiDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.
Xiaoli DengDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China. 13683657545@163.com.ORCID http://orcid.org/0000-0001-7206-7632
Hongji DuanDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.
Lin ZengThe Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, 100191, China.
Jiansuo ZhouLaboratory Medicine Department, Peking University Third Hospital, Beijing, 100191, China.
Chang LiuDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.
Xiaoyue GuoDepartment of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
Xiangyuan LiuDepartment of Rheumatology and Immunology, Peking University Third Hospital, Beijing, 100191, China.
Peking University · CN

Funding

National Natural Science Foundation of China 81501390
6 · The paper itself

Abstract

objectiveThis study aims to analyze factors related to pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes (APOs) prospectively.

methodsPatients' characteristics were described. Factors associated with obstetric complications were analyzed using logistic regression analysis.

resultsA total of 128 females with 73.4% non-criteria obstetric antiphospholipid syndrome (NC-OAPS) were included. APOs accounted for 38.3%, of which 65.3% were fetal losses. Live birth rates in criteria OAPS and NC-OAPS were similar (76.5% and 74.5%). For the whole patients, antinuclear antibody (ANA) titer ≥ 1:160 (OR 5.064, 95% CI (1.509, 16.995), P = 0.009) was a risk factor for APOs and low molecular weight heparin (LMWH) use (OR 0.149, 95% CI (0.029, 0.775), P = 0.024)) was a protective factor. Age (OR 1.159, 95% CI (1.011, 1.329), P = 0.034) and previous APOs ≥ 3 times (OR 3.772, 95% CI (1.14, 12.435), P = 0.029) were risk factors for fetal loss, and LMWH use (OR 0.068, 95% CI (0.009, 0.486), P = 0.007) was a protective factor. Regular rheumatology visits was a protective factor for APOs and fetal loss (OR 0.085, 95% CI (0.024, 0.306), P < 0.001; OR 0.019, 95% CI (0.004, 0.104), P < 0.001). The proportion of it decreased in APOs and fetal loss groups (53.1% and 28.1%). Glucocorticoid use was a risk factor for APOs in NC-OAPS and higher serum C3 levels in the first gestational trimester was a protective factor for fetal loss (OR 3.703, 95% CI (1.402, 9.777), P = 0.008; OR 0.041, 95% CI (0.002, 0.947), P = 0.046).

conclusionAge, APO history, ANA titer, LWMH and glucocorticoid use, serum C3 levels, and regular rheumatology visits were related to obstetric complications. Key Points • This was one of the few prospective studies focused on patients with positive antiphospholipid antibodies and previous adverse pregnancy outcomes. The majority were NC-OAPS patients. • The study first evaluated the impact of rheumatologists' monitoring based on individual disease assessments on pregnancy outcomes. The live birth proportion was similar in patients with criteria OAPS and NC-OAPS when treated. • Age, APO history (≥ 3 times), ANA titer (≥ 1:160), LMWH use, glucocorticoid use, and serum C3 were factors related to obstetric complications.

Indexed as

Antiphospholipid SyndromePregnancy ComplicationsAntibodies, AntiphospholipidFemaleHeparin, Low-Molecular-WeightHumansPregnancyPregnancy OutcomeProspective StudiesAntibodies, AntiphospholipidHeparin, Low-Molecular-WeightAdverse pregnancy outcomesAntiphospholipid syndromeNon-criteriaRisk factors

Identifiers

PMID32514680
OpenAlexW3034019771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.